探索脂质修饰药物和异常性肺纤维化之间的因果关系:一种药物向的门德尔随机化研究
Gexiang Cai1, Jingjing Liu1, Mengsi Cai1
1Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Lipids in health and disease
|August 1, 2024
概括
这项研究发现血脂水平与异常性肺纤维化 (IPF) 风险之间没有直接联系. 然而,用于降低胆固醇的PCSK9抑制剂可能会矛盾地增加IPF风险,需要进一步研究.
科学领域:
- 遗传学 是一个遗传学.
- 代谢障碍 代谢障碍 代谢障碍
- 肺部医学 肺部医学
背景情况:
- 异形性肺纤维化 (IPF) 是一种进展性肺病,其病因不明,治疗方法有限.
- 脂质代谢的失调是IPF发展的潜在因素.
- 对降脂剂和IPF风险的观察性研究显示了不一致的结果.
研究的目的:
- 使用孟德尔随机化 (MR) 调查循环脂质特征与IPF风险之间的关联.
- 评估脂质修饰药物对IPF风险的潜在影响.
主要方法:
- 利用了来自英国生物银行和FinnGen的5个脂质特征和IPF的总结统计数据.
- 采用各种MR方法 (反变量加权,污染混合物,强度调整的档案得分,加权中位数,加权模式,MR-Egger) 来评估因果关系.
- 使用基于摘要数据的门德尔随机化 (SMR) 来分析药物标的基因表达数据.
- 进行敏感性分析以确保可靠性并识别潜在的偏见.
主要成果:
- 在基因预测的循环脂质特征和IPF风险之间没有发现显著的关联.
- 对NPC1L1,PCSK9,ABCG5,ABCG8和APOC3的遗传抑制与IPF风险增加有关.
- SMR分析表明,全血PCSK9基因表达与IPF风险降低有关.
结论:
- 血清脂类水平似乎没有显著影响IPF风险.
- PCSK9抑制剂可能通过与其降脂效应不同的机制增加IPF风险,这需要进一步调查.
更多相关视频
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
613
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
613
01:19Antiasthma Drugs: Leukotriene Modifiers
268
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
268
01:26Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
36
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
36
00:57Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
75
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
75